Summary
The DECIDE study demonstrates that the humanized monoclonal antibody daclizumab high-yield process is superior to interferon beta-1a on brain magnetic resonance imaging measures of disease activity in patients with relapsing-remitting multiple sclerosis, supporting previous findings of a reduction in the annualized relapse rate.
- daclizumab high-yield process
- DECIDE
- relapsing-remitting multiple sclerosis
- brain MRI lesion activity
- interferon beta-1a
- T2 hyperintense
- T1 hypointense
- neurology clinical trials
- demyelinating diseases
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.